Article
Biochemistry & Molecular Biology
Ryohei Annen, Satoshi Kato, Satoru Demura, Shinji Miwa, Akira Yokka, Kazuya Shinmura, Noriaki Yokogawa, Noritaka Yonezawa, Motoya Kobayashi, Yuki Kurokawa, Toshifumi Gabata, Hiroyuki Tsuchiya
Summary: We investigated the abscopal effect after cryoablation on bone metastasis in a mouse model. The results showed that cryoablation alone had a significant immunoenhancing effect, which was further enhanced by combination treatment with PD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Yi Na Yoon, Eunju Lee, Young-Ju Kwon, Jeong-An Gim, Tae-Jin Kim, Jae-Sung Kim
Summary: The combined use of PI3K delta/gamma inhibitors and radiotherapy promotes systemic antitumor immunity by attenuating the activity of immune suppressive cells and converting the tumor microenvironment into an immune-stimulatory one. This preclinical study provides evidence for the potential use of the PI3K delta/gamma inhibitor as an immune-regulatory radiosensitizer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Qiao Liu, Lisha Wang, Huayu Lin, Zhiming Wang, Jialin Wu, Junyi Guo, Shuqiong Wen, Ling Ran, Zhengliang Yue, Xingxing Su, Qing Wu, Jianfang Tang, Zhirong Li, Li Hu, Lifan Xu, Lilin Ye, Qizhao Huang
Summary: Cytotoxic CD8(+) T cells are the main focus of anti-tumor immunity and immunotherapy research, but transferred tumor-specific CD8(+) T cells have limited effect on suppressing tumor growth. On the other hand, CD4(+) T cells play an important role in curtailing tumor metastasis.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jin-Zhi Lai, Yan-Yang Zhu, Ying Liu, Lin-Lin Zhou, Li Hu, Ling Chen, Qiu-Yu Zhang
Summary: This study found a positive correlation between tumor immunogenicity and the abscopal effect of radiotherapy, with highly immunogenic tumors being more responsive to radiation-induced abscopal effects. The research highlighted the importance of tumor heterogeneity in predicting therapeutic efficacy and the impact of tumor immunogenic subtypes on clinical outcomes when combining radiotherapy with immunotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Xia Liu, Fusheng Si, David Bagley, Feiya Ma, Yuanqin Zhang, Yan Tao, Emily Shaw, Guangyong Peng
Summary: Current study demonstrates that both mouse malignant tumor cells and regulatory T cells can induce T cell senescence, which can be prevented by blocking ATM-associated DNA damage and/or MAPK signaling pathways, resulting in enhanced antitumor immunity. Targeting effector T cell senescence, in combination with anti-PD-L1 checkpoint blockade, proves to be an effective strategy to synergistically enhance cancer immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Zhaoyun Liu, Zhiyong Yu, Dawei Chen, Vivek Verma, Chenxi Yuan, Minglei Wang, Fei Wang, Qing Fan, Xingwu Wang, Yang Li, Yuequn Ma, Meng Wu, Jinming Yu
Summary: This study demonstrates the critical role of tumor-draining lymph nodes (TDLN) in inducing abscopal effects and anti-tumor immunity in immunotherapy combined with radiation therapy. Bilateral TDLN promotes the infiltration of CD8(+) T cells and maintains the M1/M2 macrophage ratio.
CANCER COMMUNICATIONS
(2022)
Article
Cell Biology
Xia Liu, Celine L. Hartman, Lingyun Li, Carolyn J. Albert, Fusheng Si, Aiqin Gao, Lan Huang, Yangjing Zhao, Wenli Lin, Eddy C. Hsueh, Lizong Shen, Qixiang Shao, Daniel F. Hoft, David A. Ford, Guangyong Peng
Summary: The functional state of T cells is critical for effective antitumor immunity. T cell senescence driven by malignant tumor cells and regulatory T cells is a common feature in cancers, characterized by unbalanced lipid metabolism and accumulation of lipid droplets. Inhibition of group IVA phospholipase A(2) can reprogram effector T cell lipid metabolism, prevent T cell senescence, and enhance antitumor immunity and immunotherapy efficacy.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Immunology
Natalia Bowakim-Anta, Valerie Acolty, Abdulkader Azouz, Hideo Yagita, Oberdan Leo, Stanislas Goriely, Guillaume Oldenhove, Muriel Moser
Summary: Most T lymphocytes, including regulatory T cells, express the CD27 costimulatory receptor. CD27 engagement promotes the development of Th1 and cytotoxic responses in conventional T lymphocytes, but its impact on regulatory T cells is unclear. This study shows that constitutive CD27 engagement leads to the polarization of both T cell subsets into Th1-type or Tregs, characterized by cell activation, cytokine production, response to IFN-gamma, and migration to inflammatory sites dependent on CXCR3. Transfer experiments suggest that CD27 engagement activates Tregs in a cell autonomous manner. Therefore, CD27 may regulate the development of Th1 immunity in peripheral tissues and the switch of the effector response into long-term memory.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Michael L. Dixon, Jonathan D. Leavenworth, Jianmei W. Leavenworth
Summary: Regulatory T-cells, particularly effector Tregs (eTregs), play a crucial role in maintaining self-tolerance and tissue homeostasis, with potential implications in tumor development. Understanding the mechanisms that modulate the stability and suppressive function of tumoral Tregs, such as eTregs and T-FR cells, can lead to the development of more effective cancer immunotherapies that target the tumor microenvironment while minimizing systemic side effects.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Christina V. Konrad, Emma F. Iversen, Jesper D. Gunst, Ida Monrad, Andreas Holleufer, Rune Hartmann, Lars J. Ostergaard, Ole S. Sogaard, Mariane H. Schleimann, Martin Tolstrup
Summary: In this study, we have developed an immunotherapy technology that utilizes vaccination-induced CTLs to be redirected and kill antigen-expressing target cells through RoVER. This technology is highly specific and eliminates the need for adoptive transfer of CTLs.
Article
Oncology
Chantal L. Duurland, Saskia J. Santegoets, Ziena Abdulrahman, Nikki M. Loof, Gregor Sturm, Tom H. Wesselink, Ramon Arens, Sanne Boekestijn, Ilina Ehsan, Mariette I. E. van Poelgeest, Francesca Finotello, Hubert Hackl, Zlatko Trajanoski, Peter Ten Dijke, Veronique M. Braud, Marij J. P. Welters, Sjoerd H. van der Burg
Summary: The expression of CD4+CD161+ effector memory T cells is associated with improved survival in HPV16+ oropharyngeal squamous cell carcinoma. Therapeutic vaccination activates and expands CD4+CD161+ effector T cells. CD161 functions dynamically and is regulated by cell intrinsic and extrinsic factors. CD161 expressing CD4+ T cells respond more vigorously to suboptimal antigen stimulation and may amplify TCR signals.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Marko Sustic, Maja Cokaric Brdovcak, Berislav Lisnic, Jelena Materljan, Vanda Juranic Lisnic, Carmen Rozmanic, Daniela Indenbirken, Lea Hirsl, Dirk H. Busch, Ilija Brizic, Astrid Krmpotic, Stipan Jonjic
Summary: CMV vectors have the potential to induce strong immune responses, with RAE-1 gamma MCMV showing enhanced immunoprotection against bacterial and tumor challenges. The phenotypic and functional characteristics of memory CD8 T cells induced by RAE-1 gamma MCMV were distinct compared to control vectors, with differences in cytokine production and cytotoxic potential. Adoptive transfer of cells primed with RAE-1 gamma MCMV led to efficient rejection of established tumors, highlighting the importance of latent infection and cell numbers in enhancing anti-tumor responses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Faizah Alotaibi, Mark Vincent, Wei-Ping Min, James Koropatnick
Summary: CD5, a marker for T cells and a subset of B cells, is negatively correlated with anti-tumor activity in lung cancer patients, potentially impairing activation of anti-tumor T cells. T cells with high CD5 levels in tumors and lymphoid organs exhibit higher levels of activation and effector function, indicating that CD5 may be a therapeutic target for immunotherapeutic activation in cancer therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Francesco De Sanctis, Alessia Lamolinara, Federico Boschi, Chiara Musiu, Simone Caligola, Rosalinda Trovato, Alessandra Fiore, Cristina Frusteri, Cristina Anselmi, Ornella Poffe, Tiziana Cestari, Stefania Cane, Silvia Sartoris, Rosalba Giugno, Giulia Del Rosario, Barbara Zappacosta, Francesco Del Pizzo, Matteo Fassan, Erica Dugnani, Lorenzo Piemonti, Emanuela Bottani, Ilaria Decimo, Salvatore Paiella, Roberto Salvia, Rita Teresa Lawlor, Vincenzo Corbo, Youngkyu Park, David A. Tuveson, Claudio Bassi, Aldo Scarpa, Manuela Iezzi, Stefano Ugel, Vincenzo Bronte
Summary: PDAC tumors exhibit strong immunosuppressive characteristics that limit the success of immunotherapy. Research shows that reprogramming the tumor microenvironment by intervening in RNS production can enhance the efficacy of immune-based treatments.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Vivien Koh, Jayati Chakrabarti, Meaghan Torvund, Nina Steele, Jennifer A. Hawkins, Yoshiaki Ito, Jiang Wang, Michael A. Helmrath, Juanita L. Merchant, Syed A. Ahmed, Asim Shabbir, Jimmy Bok Yan So, Wei Peng Yong, Yana Zavros
Summary: The study shows that PD-L1 expression in gastric cancer is mediated by Hh and mTOR signaling pathways. Patient-derived organoid/immune cell co-cultures can be used to study immunosuppressive MDSC function. DSP analysis reveals infiltration of immunosuppressive MDSCs in gastric cancer tissues.